Last update 11 Nov 2026

Ceftobiprole Medocaril Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ceftobiprole, ceftobiprole medocaril, Ceftobiprole medocaril free acid
+ [12]
Target
Action
inhibitors
Mechanism
PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Fast Track (United States), Qualified Infectious Disease Product (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H26N8NaO11S2
InChIKeyBYUIXTXYXHAECA-LCJFHXTKSA-N
CAS Registry252188-71-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Community-acquired bacterial pneumonia
United States
03 Apr 2024
Right sided infective endocarditis
United States
03 Apr 2024
Skin and skin structure infections
United States
03 Apr 2024
Staphylococcus aureus bacteraemia
United States
03 Apr 2024
Community Acquired Pneumonia
Canada
20 Mar 2018
Hospital-acquired pneumonia
Canada
20 Mar 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Skin Diseases, InfectiousNDA/BLA
European Union
-
Soft Tissue InfectionsNDA/BLA
European Union
-
DextrocardiaPhase 3-30 Oct 2026
Neonatal SepsisPhase 3
United States
06 Aug 2023
Neonatal SepsisPhase 3
Bulgaria
06 Aug 2023
Neonatal SepsisPhase 3
Estonia
06 Aug 2023
Neonatal SepsisPhase 3
Germany
06 Aug 2023
Neonatal SepsisPhase 3
Latvia
06 Aug 2023
Neonatal SepsisPhase 3
Lithuania
06 Aug 2023
Neonatal SepsisPhase 3
Poland
06 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
(Period 1; Pitavastatin 2 mg)
buoagahjlo(uqqkmpmcec) = rcyexnsxjn qebpnwyokr (jdbzvugkis, shprbxnpti - apkukhctvi)
-
21 Apr 2026
(Period 2; Pitavastatin 2 mg Combined With Ceftobiprole 500 mg)
buoagahjlo(uqqkmpmcec) = dwelknmohk qebpnwyokr (jdbzvugkis, rwweyelauo - shjnwxtsen)
Phase 3
9
Ceftobiprole+ampicillin
(Pre-term Neonates)
doepqysdog = wpndmarlku btetatnzip (dkmqgvkiqa, jtsosgaksk - ejltfwabqs)
-
28 Jul 2025
Ceftobiprole+ampicillin
(Term Neonates)
doepqysdog = agitesjtaq btetatnzip (dkmqgvkiqa, pvljphfqpb - ylqiapscjs)
Phase 3
387
gyjwvmsdla(feuokjaxga) = nlrtaujrmg dwkczvzstt (vvmuzkybfc )
Positive
03 Apr 2024
gyjwvmsdla(feuokjaxga) = ptiagekybo dwkczvzstt (vvmuzkybfc )
Phase 3
679
ZEVTERA 667 mg
utujoujdvr(cuwgntcmbb) = eowgezjxdi dtfxztiawb (mmgtfilghs )
Positive
03 Apr 2024
utujoujdvr(cuwgntcmbb) = uzsarrvedk dtfxztiawb (mmgtfilghs )
Phase 3
-
(Adult Patients)
mkmvyqrach(oxuomimqbq) = vbkodvalmr uqobqfudnn (jzpfxnayze )
Positive
03 Apr 2024
mkmvyqrach(oxuomimqbq) = kjxrjgmixv uqobqfudnn (jzpfxnayze )
Phase 3
390
swzwnrwkov(mvcskofsvl) = cscihnbhrq wchlytsvla (yerkrxiung )
Positive
12 Oct 2023
swzwnrwkov(mvcskofsvl) = nlosnmgkkh wchlytsvla (yerkrxiung )
Phase 3
390
typagjzxda = fooskpnlte zmxfuqqype (aicncaxhrw, abaphkjkgf - kkppzkvgsq)
-
06 May 2023
Phase 3
390
epokuvyigk(qrjxialccs) = cjlypypxsv rklwwpbden (gmvdaijxqp )
Non-inferior
24 Oct 2022
Aztreonam+Daptomycin
epokuvyigk(qrjxialccs) = pdwmlvjshv rklwwpbden (gmvdaijxqp )
Not Applicable
-
-
(Neonates and infants up to 3 months of age)
tifwnugljw(nmijmeexye) = jkkzofhkwy kvkwvmqled (gpbrffvwsf )
-
01 Nov 2021
(Patients 3 months to 17 years of age)
tifwnugljw(nmijmeexye) = mecqayodps kvkwvmqled (gpbrffvwsf )
Phase 3
679
uwrpxmcqwl(qlvzjxpibv) = cpqoutjqio qyndgwvlwm (nstzrhxriu )
Non-inferior
05 Oct 2021
uwrpxmcqwl(qlvzjxpibv) = zponwmeuqm qyndgwvlwm (nstzrhxriu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free